Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Phase 1

Recruiting

Conditions: Allogeneic Hematopoietic Stem Cell Transplant Recipient
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Etoposide
Radiation: Fractionated Stereotactic Radiation Therapy
Drug: Goat Milk
Biological: Palifermin
Drug: Sirolimus
Drug: Tacrolimus

First Posted Date: 2019-11-26

Last Posted Date: 2024-01-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 36

Registration Number: NCT04177004

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Early Phase 1

Active, not recruiting

Conditions: ALL, Childhood B-Cell

Interventions: Genetic: alloCART-19
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-11-22

Last Posted Date: 2024-03-15

Lead Sponsor: Children's Hospital of Fudan University

Target Recruit Count: 6

Registration Number: NCT04173988

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, Minhang, China

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: PBCAR269A
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Nirogacestat

First Posted Date: 2019-11-21

Last Posted Date: 2023-09-21

Lead Sponsor: Precision BioSciences, Inc.

Target Recruit Count: 48

Registration Number: NCT04171843

Locations: 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 2 locations

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Phase 2

Active, not recruiting

Conditions: Breast Cancer
Neoadjuvant Chemotherapy

Interventions: Drug: Doxorubicin liposome
Drug: Cyclophosphamide
Drug: Trastuzumab
Drug: Docetaxel
Drug: Epirubicin
Drug: Pertuzumab
Drug: Paclitaxel-albumin
Drug: Paclitaxel

First Posted Date: 2019-11-21

Last Posted Date: 2023-10-16

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 156

Registration Number: NCT04172259

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma
Extramedullary Plasmacytoma

Interventions: Drug: Daratumumab
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2019-11-18

Last Posted Date: 2022-11-08

Lead Sponsor: Stichting European Myeloma Network

Target Recruit Count: 41

Registration Number: NCT04166565

Locations: 🇬🇷
Anticancer Hospital of Thessaloniki, Thessaloníki, Greece
🇮🇹
University of Bologna, Bologna, Italy
🇮🇹
Univerity of Turin, Torino, Italy

and more 5 locations

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

Conditions: Relapse/Refractory Mantle Cell Lymphoma

First Posted Date: 2019-11-14

Last Posted Date: 2021-10-14

Lead Sponsor: Kite, A Gilead Company

Registration Number: NCT04162756

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

and more 6 locations

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Non-hodgkins
Lymphoma, B-Cell
B-Cell Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia

Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-11-12

Last Posted Date: 2022-02-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT04160195

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Autologous Transplant Targeted Against Crohn's

Phase 2

Withdrawn

Conditions: Crohn's Disease

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mesna
Drug: Alemtuzumab
Drug: G-CSF
Drug: Rifaximin
Drug: Tacrolimus

First Posted Date: 2019-11-06

Last Posted Date: 2019-11-08

Lead Sponsor: Northwestern University

Registration Number: NCT04154735

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Acute Leukemia
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes

Interventions: Drug: CD8+ Memory T Cell Infusion
Drug: Thiotepa
Drug: Fludarabine
Radiation: Hyperfractionated TBI
Drug: Busulfan
Drug: Cyclophosphamide

First Posted Date: 2019-11-05

Last Posted Date: 2024-10-17

Lead Sponsor: Robert Lowsky

Target Recruit Count: 7

Registration Number: NCT04151706

Locations: 🇺🇸
Stanford Medical Center, Stanford, California, United States

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Advanced Cancer
Pancreatic Ductal Adenocarcinoma
Pancreatic Neoplasms

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells
Drug: Anti-PD-1 monoclonal antibody

First Posted Date: 2019-10-31

Last Posted Date: 2023-09-01

Lead Sponsor: Changhai Hospital

Target Recruit Count: 30

Registration Number: NCT04146298

Locations: 🇨🇳
Changhai Hospital, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy